Changes in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving granulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection

TitleChanges in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving granulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection
Publication TypeJournal Article
Year of Publication1999
AuthorsFroberg MK, Garg UC, Stroncek DF, Geis M, McCullough J, Brown DM
JournalTransfusion
Volume39
Issue4
Pagination410 - 4
Date PublishedApr
ISSN0041-1132 (Print) 0041-1132 (Linking)
Accession Number10220269
Keywords*Blood Donors, *Hematopoietic Stem Cells, Alkaline Phosphatase / *blood, Bone and Bones / *drug effects / enzymology, Granulocyte Colony-Stimulating Factor / *adverse effects, Humans, Osteocalcin / *blood, Pain / *etiology
Abstract

BACKGROUND: Granulocyte-colony-stimulating factor (G-CSF) has been used to increase the number of CD34+ peripheral blood stem and progenitor cells collected by apheresis for use in autologous or allogeneic progenitor cell transplantation. The most frequent side effect of G-CSF treatment is bone pain, which occurs in over 80 percent of healthy progenitor cell donors. STUDY DESIGN AND METHODS: The possible mechanism of bone pain was investigated by measuring serum levels of osteocalcin (OC), bone-specific alkaline phosphatase (BAP), acid phosphatase (ACP), and tartrate-resistant acid phosphatase (TRAP) in seven healthy progenitor cell donors treated with human recombinant G-CSF administered subcutaneously for 5 consecutive days. RESULTS: All seven patients experienced bone pain during the treatment period. Serum levels of OC, BAP, ACP, and TRAP were measured in blood samples drawn on Days 0, 4, 5, 6, and 14. Levels of BAP were increased (p

Notify Library Reference ID554

Related Incidents